Recruitment in NATiV3 clinical trial progresses with over 85% of the targeted number of patients enrolled in the main cohort and a statistical powering of the study expected to be superior to 95% for ...

Recruitment in NATiV3 clinical trial progresses with over 85% of the targeted number of patients enrolled in the main cohort and a statistical ...

With the growing demand for innovative healthcare services, increasing spending, and rising tech adoption, the healthcare ...

Genespire could soon be joining it, as the financing announced Wednesday will help advance GENE202 into Phase 1/2 trials. Preclinical results presented at a medical meeting in May suggested the ...

The health-tech startup was awarded two grants totaling more than $3 million to help it fight Alzheimer’s disease and ...

Now, a heart simulator that replicates the complicated movements and functions of a real human heart has been created. The University of New South Wales researchers are behind this development. In ...

BioAge Labs (BIOA), which is developing a drug to augment popular weight-loss medications such as Wegovy and Zepbound, has upsized its proposed IPO. Read more here.

The transfer of knowledge from animal models to humans is essential for unraveling disease mechanisms and developing precise ...

Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in ...

Cassava Sciences' stock rose 9% after completing a trial of its Alzheimer's drug, Simufilam, but the company's future remains ...

OncoC4 is taking AcroImmune—and its in-house clinical manufacturing capabilities—under its wing in an all-stock merger. | ...

The epigenetic drugs space has witnessed a two-fold increase in Series A venture funding, with total deal value increasing to ...